Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antihypertensive therapy in renal dysfunction].

Sadayoshi Ito1

  • 1Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.

American journal of hypertension·2025
Same author

Deep learning-based histopathological assessment of tubulo-interstitial injury in chronic kidney diseases.

Communications medicine·2025
Same author

Severe influenza A viral pneumonia in a hemodialysis patient: successful treatment with steroid pulse therapy.

CEN case reports·2024
Same author

Role of radiologists in the diagnosis and management of adrenal disorders.

Endocrine journal·2024
Same author

Once in a Lifetime~Dream, Passion, Challenge, and Respect for Peers~.

Endocrine journal·2024
Same author

Screening Cutoff Values for the Detection of Aldosterone-Producing Adenoma by LC-MS/MS and a Novel Noncompetitive CLEIA.

Journal of the Endocrine Society·2024

Renin-angiotensin system (RAS) inhibition benefits diabetic patients with kidney issues, despite potential risks like reduced kidney function. This review covers managing these risks and optimizing antihypertensive therapy.

Area of Science:

  • Nephrology
  • Cardiology
  • Diabetology

Background:

  • Antihypertensive treatment is crucial for preventing cardiovascular events and kidney disease in diabetics.
  • Renin-angiotensin system (RAS) inhibition offers benefits beyond blood pressure reduction.
  • RAS inhibitors can sometimes worsen renal function and cause hyperkalemia in patients with kidney dysfunction.

Purpose of the Study:

  • To discuss conditions leading to RAS inhibition-induced renal decline in diabetic patients.
  • To outline strategies for managing these adverse renal effects.
  • To explore combination antihypertensive therapies based on renal function and proteinuria.

Main Methods:

  • Review of clinical studies and existing literature on RAS inhibition in diabetic patients with renal dysfunction.

Related Experiment Videos

  • Analysis of factors contributing to renal function decline and hyperkalemia.
  • Discussion of therapeutic approaches and combination strategies.

    • Main Results:

    • RAS inhibition is particularly beneficial for diabetic patients with renal dysfunction, despite potential risks.
    • Specific conditions and risk factors for renal decline and hyperkalemia during RAS inhibition are identified.
    • Management strategies and tailored combination therapies can mitigate risks and optimize outcomes.

    Conclusions:

    • RAS inhibition is a valuable therapeutic strategy in diabetic nephropathy and cardiovascular risk reduction.
    • Careful monitoring and management are essential to mitigate risks associated with RAS inhibition in renal dysfunction.
    • Personalized combination antihypertensive therapy is recommended based on individual patient profiles.